Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant properties


Por: Escola-Gil, JC, Chen, XY, Julve, J, Quesada, H, Santos, D, Metso, J, Tous, M, Jauhiainen, M, Blanco-Vaca, F

Publicada: 1 abr 2013
Resumen:
Hepatic lipase (HL) and endothelial lipase (EL) are negative regulators of plasma HDL cholesterol (HDLc) levels and presumably could affect two main HDL atheroprotective functions, macrophage-to-feces reverse cholesterol transport (RCT) and HDL antioxidant properties. In this study, we assessed the effects of both HL and EL deficiency on macrophage-specific RCT process and HDL ability to protect against LDL oxidation. HL- and EL-deficient and wild-type mice were injected intraperitoneally with [H-3]cholesterol-labeled mouse macrophages, after which the appearance of [H-3]cholesterol in plasma, liver, and feces was determined. The degree of HDL oxidation and the protection of oxidative modification of LDL co-incubated with HDL were evaluated by measuring conjugated diene kinetics. Plasma levels of HDLc, HDL phospholipids, apoA-I, and platelet-activated factor acetyl-hydrolase were increased in both HL- and EL-deficient mice. These genetically modified mice displayed increased levels of radiolabeled, HDL-bound [H-3]cholesterol 48 h after the label injection. The magnitude of macrophage-derived [H-3]cholesterol in feces was also increased in both the HL- and EL-deficient mice. HDL from the HL- and EL-deficient mice was less prone to oxidation and had a higher ability to protect LDL from oxidation, compared with the HDL derived from the wild-type mice. These changes were correlated with plasma apoA-I and apoA-I/HDL total protein levels. In conclusion, targeted inactivation of both HL and EL in mice promoted macrophage-to-feces RCT and enhanced HDL antioxidant properties. (C) 2013 Elsevier B.V. All rights reserved.

Filiaciones:
Escola-Gil, JC:
 IIB Sant Pau, Barcelona 08025, Spain

 CIBERDEM, CIBER Diabet & Enfermedades Metab Asociadas, Barcelona 08036, Spain

Chen, XY:
 IIB Sant Pau, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Barcelona 08025, Spain

Julve, J:
 IIB Sant Pau, Barcelona 08025, Spain

 CIBERDEM, CIBER Diabet & Enfermedades Metab Asociadas, Barcelona 08036, Spain

Quesada, H:
 IIB Sant Pau, Barcelona 08025, Spain

Santos, D:
 CIBERDEM, CIBER Diabet & Enfermedades Metab Asociadas, Barcelona 08036, Spain

Metso, J:
 Biomedicum, Natl Inst Hlth & Welf, Helsinki, Finland

 Biomedicum, FIMM Inst Mol Med Finland, Helsinki, Finland

Tous, M:
 IIB Sant Pau, Barcelona 08025, Spain

Jauhiainen, M:
 Biomedicum, Natl Inst Hlth & Welf, Helsinki, Finland

 Biomedicum, FIMM Inst Mol Med Finland, Helsinki, Finland

Blanco-Vaca, F:
 IIB Sant Pau, Barcelona 08025, Spain

 CIBERDEM, CIBER Diabet & Enfermedades Metab Asociadas, Barcelona 08036, Spain

 Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Barcelona 08025, Spain
ISSN: 13881981
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 1831 Número: 4
Páginas: 691-697
WOS Id: 000316438200003
ID de PubMed: 23328279

MÉTRICAS